MOUNTAIN VIEW, Calif. — Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, said Andrew Miller, Ph.D., has joined its board of directors.
Miller’s appointment became effective May 27.
“We are thrilled to welcome Andrew to Alto’s Board at a transformative time for the Company,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. “Few leaders in our industry have done more to advance the science and commercial reality of new medicines for serious mental illness. Andrew’s firsthand experience translating novel neuropsychiatric mechanisms into approved therapies — and building a category-defining company around them — will be invaluable as we execute on our potentially pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression and advance multiple additional readouts across our precision psychiatry pipeline.”
Miller is a biopharmaceutical executive with experience in neuropsychiatric drug development, corporate strategy and value creation. He most recently was founder and president of research and development at Karuna Therapeutics, where he was the lead inventor of KarXT, now marketed by Bristol Myers Squibb as COBENFY for the treatment of schizophrenia.
Alto said COBENFY was the first novel mechanism approved for schizophrenia in decades. Miller previously served as Karuna’s chief operating officer, chief executive officer and a member of its board of directors. He helped guide the company through its $14 billion acquisition by Bristol Myers Squibb in 2024.
“Psychiatry remains one of the largest areas of unmet medical need in all of healthcare. Far too many patients with depression, schizophrenia, and other serious mental illnesses are left without treatments that truly work for them,” said Dr. Miller. “Alto’s pipeline reflects a clear-eyed focus on changing that — advancing novel mechanisms with the potential to deliver substantially better outcomes. I’m honored to join the Board and look forward to helping the team realize that vision for patients.”
Miller was named to Time magazine’s 100 Next Generation Leaders and 100 Most Influential People in Healthcare for 2025.
He currently serves as chairman of the board of Progentos Therapeutics and as a board member of Montara Therapeutics. He is also an adviser to GV, General Atlantic, Vida Ventures, Longwood Fund and the One Mind Foundation.
Miller holds a Ph.D. in chemical engineering from the Massachusetts Institute of Technology and a B.S. in chemical engineering from the University of Illinois at Urbana-Champaign.
